Vaccinex Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	Current	2023	2022	2021	2020	2019	2018	2017	2016
Market Capitalization	8	8	28	32	46	72	42	-	-
Market Cap Growth	-	-69.83%	-14.05%	-30.87%	-35.72%	72.34%	-	-	-
Enterprise Value	7	7	22	24	45	69	22	-1	-1
PE Ratio	-0.41	-0.41	-1.39	-1.43	-1.61	-2.26	-1.42	-	-
PS Ratio	14.57	14.57	100.12	35.59	74.14	137.83	57.77	-	-
PB Ratio	-3.59	-3.59	5.30	4.32	-1.74	-2.75	-4.85	-	-
P/FCF Ratio	-0.48	-0.48	-1.44	-1.26	-1.60	-2.34	-1.64	-	-
P/OCF Ratio	-0.48	-0.48	-1.44	-1.27	-1.62	-2.35	-1.65	-	-
EV/Sales Ratio	12.31	12.31	78.64	26.48	71.92	132.52	30.53	-15.19	-1.97
EV/EBITDA Ratio	-0.35	-0.35	-1.10	-1.11	-1.60	-2.19	-0.76	0.08	0.06
EV/EBIT Ratio	-0.35	-0.35	-1.09	-1.10	-1.58	-2.18	-0.76	0.08	0.06
EV/FCF Ratio	-0.41	-0.41	-1.13	-0.94	-1.55	-2.25	-0.87	0.06	0.03
Debt / Equity Ratio	-0.11	-0.11	0.09	0.05	-0.35	-	-	-0.02	-0.01
Debt / EBITDA Ratio	-0.01	-0.01	-0.02	-0.02	-0.33	-	-	-0.16	-0.10
Debt / FCF Ratio	-0.01	-0.01	-0.03	-0.02	-0.32	-	-	-0.13	-0.05
Quick Ratio	0.42	0.42	2.59	3.81	0.82	0.53	3.05	1.03	0.40
Current Ratio	0.57	0.57	2.95	4.17	0.86	0.58	3.20	1.19	0.48
Asset Turnover	0.16	0.16	0.02	0.05	0.07	0.06	0.05	0.02	-
Interest Coverage	-20250.00	-20250.00	-9906.50	-26.66	-58.00	-	-74.30	-12.79	-3.66
Return on Equity (ROE)	1927.30%	1927.30%	-205.10%	-241.60%	113.10%	141.20%	41.90%	18.90%	-
Return on Assets (ROA)	-571.70%	-571.70%	-167.60%	-112.60%	-300.50%	-355.70%	-191.80%	-521.20%	-
Return on Capital (ROIC)	1108.77%	1108.77%	-350.58%	-288.26%	163.13%	122.02%	316.45%	17.21%	19.11%
Earnings Yield	-243.83%	-243.81%	-71.97%	-69.87%	-62.26%	-44.20%	-70.57%	-	-
FCF Yield	-208.31%	-208.29%	-69.64%	-79.07%	-62.45%	-42.72%	-60.99%	-	-
Buyback Yield / Dilution	-129.44%	-129.44%	-47.10%	-53.56%	-45.85%	-146.59%	-374.06%	-6.13%	-
Total Shareholder Return	-129.44%	-129.44%	-47.10%	-53.56%	-45.85%	-146.59%	-374.06%	-6.13%	-

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).